My ePortfolio Register   

Impact of recurrent myeloma alterations on drug response

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.03.17
Views: 693

Dr Muntasir Mamun Majumder - University of Helsinki, Helsinki, Finland

Dr Majumder speaks with ecancer at the 16th International Myeloma Workshop about increased mutational burden and alterations to DNA damage repair genes are associated with poor prognosis and sensitivity to PI3K-mTOR inhibitors in multiple myeloma.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence